Javascript is required to run this page

HB1436

Prescription drugs; price transparency.

Status:
Killed

Chief Patron:
Chris Hurst (D)

Session:
2018 Regular Session

Summary

As Introduced. Prescription drug price transparency.

Requires every manufacturer of a prescription drug that is made available in the Commonwealth and has a wholesale acquisition price of $10,000 or more for a single course of treatment to report to the State Health Commissioner no later than July 1 of each year information related to the cost of developing, manufacturing, and marketing the prescription drug; any changes in the average wholesale price and average wholesale acquisition cost of the prescription drug; the amount of profits derived from sale of the prescription drug; and the total amount of financial assistance provided to consumers of the prescription drug. The bill adds this reported data to the list of reports that the Commissioner causes to be published on a website maintained by a nonprofit entity with which the Commissioner has entered into a contract for such purpose and requires the Commissioner to annually report on such information, in aggregate form, to the Chairmen of the House Committees on Appropriations and on Health, Welfare and Institutions and the Senate Committees on Finance and on Education and Health. The measure has a delayed effective date of January 1, 2019. (Less)

  • Bill History

  • 01/16/2018 - House: Presented and ordered printed 18101421D
  • 01/16/2018 - House: Referred to Committee on Health, Welfare and Institutions
  • 01/23/2018 - House: Referred from Health, Welfare and Institutions
  • 01/23/2018 - House: Referred to Committee on Commerce and Labor
  • 01/31/2018 - House: Impact statement from VDH (HB1436)
  • 02/01/2018 - House: Passed by indefinitely in Commerce and Labor (11-Y 6-N)

Full text and vote history:

Virginia Legislative Information System

RichmondSunlight.com

See other bills related to: